Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A Case Report

Clin Lung Cancer. 2022 Sep;23(6):e339-e341. doi: 10.1016/j.cllc.2022.04.007. Epub 2022 May 5.

Authors

Michelle R Sproat¹, Mara Lacy Hofherr², Siddhartha Devarakonda³

Affiliations

¹ Clinical Oncology Pharmacist, Washington University School of Medicine In St Louis / Division of Oncology, St. Louis, MO. Electronic address: m.sproat@wustl.edu.
² Clinical Oncology Pharmacist, Washington University School of Medicine In St Louis / Division of Oncology, St. Louis, MO.
³ Assistant Professor of Medicine, Washington University School of Medicine In St Louis / Division of Oncology, St. Louis, MO.

PMID: 35643747
DOI: 10.1016/j.cllc.2022.04.007

No abstract available

Keywords: Chronic renal failure; Hemodialysis; KRAS G12C-mutation; KRAS inhibitor; Oral Chemotherapy.

Publication types

Case Reports

MeSH terms

Adenocarcinoma of Lung* / drug therapy
Humans
Kidney Failure, Chronic* / therapy
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology
Mutation
Piperazines
Proto-Oncogene Proteins p21(ras)
Pyridines
Pyrimidines
Renal Dialysis

Substances

Piperazines
Pyridines
Pyrimidines
sotorasib
Proto-Oncogene Proteins p21(ras)